ArticleLeukemia2019
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
Open access · hybridAbstract read
In one paragraph
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin.Leukemia · 2026Article
- Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.American journal of hematology · 2025Review
- Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.British journal of haematology · 2025Article
- KIT-Negative Systemic Mastocytosis Associated With Acute Myeloid Leukemia.Case reports in oncological medicine · 2025Article
- Can molecular patterns help to classify overlapping entities in myeloid neoplasms?Histopathology · 2025Review
- Unraveling the Rare Entity ofJournal of hematology · 2024Article
- Review
- A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML.Blood advances · 2024Article
- Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.International journal of molecular sciences · 2023Review
- Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.Annals of hematology · 2023Article
- A case of high-risk AML in a patient with advanced systemic mastocytosis.Clinical case reports · 2023Article
- Therapy-related core binding factor acute myeloid leukemia.International journal of hematologic oncology · 2023Review
- Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia.Heliyon · 2022Article
- Article
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.HemaSphere · 2021Review
- Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITLeukemia · 2021Article
- Core binding factor acute myeloid leukemia: Advances in the heterogeneity ofMolecular and clinical oncology · 2020Review
- Detection of the KITModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- CEBPE expression is an independent prognostic factor for acute myeloid leukemia.Journal of translational medicine · 2019Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 13 institutions in 4 countries.
Mohamad JawharDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Sebastian KreilDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Juliana SchwaabDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Khalid ShoumariyehDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Manja MeggendorferMunich Leukemia Laboratory, Munich, Germany.
Lambert L F SpanDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Stephan FuhrmannDepartment of Hematology and Oncology, HELIOS Hospital, Berlin, Germany.
Nicole NaumannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Hans-Peter HornyInstitute of Pathology, Ludwig-Maximilians-University, Munich, Germany.
Karl SotlarInstitute of Pathology, Medical University of Salzburg, Salzburg, Austria.
Boris KubuschokDepartment of Internal Medicine I, José-Carreras Centrum for Immuno- and Gene Therapy, University of Saarland Medical School, Homburg/Saar, Germany.
Nikolas von BubnoffDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Karsten SpiekermannDepartment of Medicine III, University Hospital of Munich, Munich, Germany.
Michael HeuserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Georgia MetzgerothDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Stefan KleinDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Hanneke C Kluin-NelemansDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Torsten HaferlachMunich Leukemia Laboratory, Munich, Germany.
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Nicholas C P CrossWessex Regional Genetics Laboratory, Salisbury, UK.ORCID http://orcid.org/0000-0001-5481-2555
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Peter ValentDepartment of Internal Medicine I, Division of Hematology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. andreas.reiter@medma.uni-heidelberg.de.
Heidelberg University · DELudwig Boltzmann Institute for Cardiovascular Research · ATMunich Leukemia Laboratory (Germany) · DEUniversity Hospital Ulm · DEUniversity Medical Center Groningen · NLUniversity of Freiburg · DEHelios Hospital Berlin-Buch · DELMU Klinikum · DELudwig-Maximilians-Universität München · DEMedizinische Hochschule Hannover · DESaarland University · DEUniversity of Salzburg · ATWessex Regional Genetics Laboratory · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
KIT D816 mutations (KIT D816
Indexed as
AllelesMutationAdultAgedAged, 80 and overBiomarkersBone MarrowCore Binding FactorsCytogenetic AnalysisFemaleGene FrequencyHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceKaplan-Meier EstimateLeukemia, Myeloid, AcuteBiomarkersCore Binding FactorsProto-Oncogene Proteins c-kit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.